[Visceral leishmaniasis associated with Wegener disease. Use of lipid complex amphotericin B and liposomal amphotericin B].
BACKGROUND
Leishmaniasis in a patient with Wegenerís disease raises the problem of amphotericin toxicity further compromising the pre-existing renal disorder.


METHODS
An anemic patient treated for Wegenerís disease developed visceral leishmaniasis. This renal failure patient was treated with lipid complex amphotericin B and liposomal amphotericin B. We report outcome at 10 months follow-up.


CONCLUSIONS
The new formulations of amphotericin B allow effective treatment of visceral leishmaniasis in renal failure patients. Long-lasting results are probably favored by the interruption of immuno-suppressive therapy.
Zanaldi
H
H
Service de Médecine interne II, Hôpital de l'Archet I, Nice.
Rosenthal
E
E
Marty
P
P
Chichmanian
R M
RM
Pesce
A
A
Cassuto
J P
JP
D058186:Acute Kidney Injury / Q000188:drug therapy; D000368:Aged; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000740:Anemia / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000139:chemically induced*; D008081:Liposomes; D008297:Male; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D008081:Liposomes; D000666:Amphotericin B
Leishmaniose viscérale associée à une maladie de Wegener. Utilisation de l'amphotéricine B en complexes lipidiques et de l'amphotéricine B liposomale.